Giovanni Cioffi1,2,3, Ombretta Viapiana4, Luigi Tarantini5, Giovanni Orsolini4, Luca Idolazzi4, Federica Ognibeni4, Andrea Dalbeni6, Davide Gatti4, Angelo Fassio4, Giovanni Adami4, Maurizio Rossini4, Alessandro Giollo4. 1. Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy. dottcioffi@gmail.com. 2. Division of cardiac rehabilitation, San Pancrazio Hospital, Arco di Trento, Trento, Italy. dottcioffi@gmail.com. 3. Rheumatology Unit, Policlinico Borgo Roma, Piazzale Scuro 10, 37134, Verona, Italy. dottcioffi@gmail.com. 4. Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy. 5. Department of cardiology, Ospedale civile S. Martino, Belluno, Italy. 6. Department of Medicine, General Medicine and Hypertension Unit, University of Verona & Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
Abstract
BACKGROUND: Several studies on community populations found that metabolic syndrome (MetS) is associated with higher risk for total incident cancer with a predisposition for specific types of cancer. These findings have never been analyzed in patients with chronic inflammatory rheumatic and musculoskeletal diseases (RMD). We assessed prevalence/incidence and factors related to the development of cancer in a large cohort of these patients and evaluate whether MetS and its components were associated with cancer independent of traditional markers of inflammation. METHODS: Between March 2014 and April 2016, 474 patients with RMD involved in a cardiovascular primary prevention program were consecutively recruited into this ambispective (combination of retrospective/prospective) study. They underwent clinical, laboratory, and echocardiographic evaluations. MetS was diagnosed according to the ATPIII criteria. RESULTS: Duration of follow-up was 42 [18-60] months. Patients with a diagnosis of cancer (made before recruitment or during follow-up) were 46 (9.7%). Cancer was diagnosed in 22/76 patients (29%) with MetS and in 24/398 patients (6%, p < 0.001) without MetS; nearly two thirds of malignancies belonged to those traditionally related to MetS. MetS was the strongest cancer risk factor. Cancer was positively associated with the number of MetS components identified in each patient. Beyond MetS, cancer was associated to older age and increased inflammatory disease activity; this information allowed to build a simple performance indicator highly sensitive for cancer development. CONCLUSION: In light of our results, an increasingly accurate assessment of MetS would be required in patients with RMD as potential measure of clinical outcomes including the risk of cancer.
BACKGROUND: Several studies on community populations found that metabolic syndrome (MetS) is associated with higher risk for total incident cancer with a predisposition for specific types of cancer. These findings have never been analyzed in patients with chronic inflammatory rheumatic and musculoskeletal diseases (RMD). We assessed prevalence/incidence and factors related to the development of cancer in a large cohort of these patients and evaluate whether MetS and its components were associated with cancer independent of traditional markers of inflammation. METHODS: Between March 2014 and April 2016, 474 patients with RMD involved in a cardiovascular primary prevention program were consecutively recruited into this ambispective (combination of retrospective/prospective) study. They underwent clinical, laboratory, and echocardiographic evaluations. MetS was diagnosed according to the ATPIII criteria. RESULTS: Duration of follow-up was 42 [18-60] months. Patients with a diagnosis of cancer (made before recruitment or during follow-up) were 46 (9.7%). Cancer was diagnosed in 22/76 patients (29%) with MetS and in 24/398 patients (6%, p < 0.001) without MetS; nearly two thirds of malignancies belonged to those traditionally related to MetS. MetS was the strongest cancer risk factor. Cancer was positively associated with the number of MetS components identified in each patient. Beyond MetS, cancer was associated to older age and increased inflammatory disease activity; this information allowed to build a simple performance indicator highly sensitive for cancer development. CONCLUSION: In light of our results, an increasingly accurate assessment of MetS would be required in patients with RMD as potential measure of clinical outcomes including the risk of cancer.
Authors: Urpu Salmenniemi; Eija Ruotsalainen; Jussi Pihlajamäki; Ilkka Vauhkonen; Sakari Kainulainen; Kari Punnonen; Esko Vanninen; Markku Laakso Journal: Circulation Date: 2004-12-13 Impact factor: 29.690
Authors: Marta Fantò; Mario Stefano Peragallo; Mario Pietrosanti; Roberta Di Rosa; Andrea Picchianti Diamanti; Simonetta Salemi; Raffaele D'Amelio Journal: Intern Emerg Med Date: 2015-06-23 Impact factor: 3.397
Authors: Hervé Lebrec; Rafael Ponce; Bradley D Preston; Jan Iles; Teresa L Born; Michele Hooper Journal: Curr Med Res Opin Date: 2015-02-16 Impact factor: 2.580
Authors: Shaista Malik; Nathan D Wong; Stanley S Franklin; Tripthi V Kamath; Gilbert J L'Italien; Jose R Pio; G Rhys Williams Journal: Circulation Date: 2004-08-23 Impact factor: 29.690
Authors: J Sieper; M Rudwaleit; X Baraliakos; J Brandt; J Braun; R Burgos-Vargas; M Dougados; K-G Hermann; R Landewé; W Maksymowych; D van der Heijde Journal: Ann Rheum Dis Date: 2009-06 Impact factor: 19.103
Authors: Gabriele Nagel; Tanja Stocks; Daniela Späth; Anette Hjartåker; Björn Lindkvist; Göran Hallmans; Håkan Jonsson; Tone Bjørge; Jonas Manjer; Christel Häggström; Anders Engeland; Hanno Ulmer; Randi Selmer; Hans Concin; Pär Stattin; Richard F Schlenk Journal: Ann Hematol Date: 2012-05-16 Impact factor: 3.673
Authors: Sung Hae Chang; Jin Kyun Park; Yun Jong Lee; Ji Ae Yang; Eun Young Lee; Yeong Wook Song; Eun Bong Lee Journal: Arthritis Res Ther Date: 2014-08-28 Impact factor: 5.156